NABI BIOPHARMACEUTICALS

Company

Vaxart, Inc.

Filed

May 2, 2006

Accession Number

0000902664-06-001340

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →